Gene therapy for cystic fibrosis

UMMS Affiliation

Department of Pediatrics

Publication Date


Document Type



Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; *Gene Therapy; Genes, Recessive; Genetic Predisposition to Disease; Genetic Vectors; Humans; Immunity, Cellular; Mutagenesis, Site-Directed; Protein Transport; Signal Transduction; Stem Cells; Targeted Gene Repair


Allergy and Immunology | Genetics and Genomics | Pediatrics | Respiratory Tract Diseases


Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane conductance regulator (CFTR) gene that lead to defective ion transport in the conducting pulmonary airways and exocrine glands. Through a process that is not fully understood, CFTR defects predispose affected patients to chronic endobronchial infections with organisms such as Pseudomonas aeruginosa and Staphylococcus aureus. Following the discovery of the CFTR gene in 1989, CF became one of the primary targets for gene therapy research. Early enthusiasm surrounded the new field of gene therapy during most of the 1990s and it led academics and clinicians on a big effort to apply gene therapy for cystic fibrosis. Clinical studies have been pursued using recombinant adenovirus, recombinant adeno-associated virus, cationic liposomes, and cationic polymer vectors. Although to this date no dramatic therapeutic benefits have been observed, a lot of information has been gained from the pre-clinical and clinical studies that were performed. This learning curve has led to the optimization of vector technology and an appreciation of immune and mechanical barriers that have to be overcome for successful delivery.

DOI of Published Version



Clin Rev Allergy Immunol. 2008 Dec;35(3):164-78. Link to article on publisher's site

Journal/Book/Conference Title

Clinical reviews in allergy and immunology

Related Resources

Link to Article in PubMed

PubMed ID